Oncolys BioPharma Inc. (TYO:4588)
Japan flag Japan · Delayed Price · Currency is JPY
4,040.00
+20.00 (0.50%)
Aug 27, 2026, 11:30 AM JST

Oncolys BioPharma Cash Flow Statement

Millions JPY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-1,685-1,939-1,149-1,615-2,095
Depreciation & Amortization
0.822.290.916.494.89
Other Amortization
-8.78---
Loss (Gain) From Sale of Assets
---90.98-
Asset Writedown & Restructuring Costs
17.121.94.419.8511.14
Loss (Gain) From Sale of Investments
---21.41-321
Stock-Based Compensation
25.6310.0675.93277.48390.51
Provision & Write-off of Bad Debts
----35.68
Other Operating Activities
-9.856.15-71.31-41.7516.91
Change in Accounts Receivable
--352.15-281.5598.71
Change in Inventory
0.7618.91-12.59-1.184.44
Change in Accounts Payable
-141.35132.73-45.37-100.34-60.9
Change in Unearned Revenue
---285.76--
Change in Other Net Operating Assets
-228.42400.78-565.15-96.36-192.5
Operating Cash Flow
-2,020-1,337-1,717-1,742-1,465
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Capital Expenditures
-3.52-5.69-1.36-1.44-2.7
Sale of Property, Plant & Equipment
-0.14---
Cash Acquisitions
-----10.76
Investment in Securities
-0-021.410.49-0.01
Other Investing Activities
-1.190.160.070.01-2.35
Investing Cash Flow
-4.71-5.3920.12-0.94-37.58

Financing Activities

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Long-Term Debt Issued
100100100100100
Short-Term Debt Repaid
---100--
Long-Term Debt Repaid
-106.37-198.98-113.77-124.84-103.15
Total Debt Repaid
-106.37-198.98-213.77-124.84-103.15
Net Debt Issued (Repaid)
-6.37-98.98-113.77-24.84-3.15
Issuance of Common Stock
2,8911,242-3,128245.51
Repurchase of Common Stock
-5--0.03-0.04-0.1
Other Financing Activities
-0--0.03-12.07-0
Financing Cash Flow
2,8791,143-113.833,091242.26

Net Cash Flow

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Foreign Exchange Rate Adjustments
23.521.3367.4138.17-14.15
Miscellaneous Cash Flow Adjustments
--0-0-0
Net Cash Flow
878.16-178.44-1,7431,387-1,275

Free Cash Flow

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Free Cash Flow
-2,024-1,343-1,718-1,743-1,468
Free Cash Flow Growth
-----
Free Cash Flow Margin
-6447.89%-2129.84%-176.04%-271.33%-467.22%
Free Cash Flow Per Share
-92.69-75.44-99.18-103.06-102.00
Levered Free Cash Flow
-1,428-566.1-943.47-1,012-788.94
Unlevered Free Cash Flow
-1,425-563.85-941.01-1,009-786.34

Additional Metrics

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash Interest Paid
4.343.843.964.194.32
Cash Income Tax Paid
2.94-25.371.473.733.73
Change in Working Capital
-369.01552.41-556.72-479.43-150.24